| 000 | 01493 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250516081452.0 | ||
| 264 | 0 | _c20120717 | |
| 008 | 201207s 0 0 eng d | ||
| 022 | _a1522-1555 | ||
| 024 | 7 |
_a10.1152/ajpendo.00038.2012 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSgarra, Luca | |
| 245 | 0 | 0 |
_aDeterminants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: molecular mechanisms in the context of integrated pathophysiology. _h[electronic resource] |
| 260 |
_bAmerican journal of physiology. Endocrinology and metabolism _cMay 2012 |
||
| 300 |
_aE1171-82 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aCoronary Artery Disease _xdrug therapy |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xdrug therapy |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 |
_aEndothelium, Vascular _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadverse effects |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aRosiglitazone |
| 650 | 0 | 4 |
_aThiazolidinediones _xadministration & dosage |
| 700 | 1 | _aAddabbo, Francesco | |
| 700 | 1 | _aPotenza, Maria Assunta | |
| 700 | 1 | _aMontagnani, Monica | |
| 773 | 0 |
_tAmerican journal of physiology. Endocrinology and metabolism _gvol. 302 _gno. 10 _gp. E1171-82 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1152/ajpendo.00038.2012 _zAvailable from publisher's website |
| 999 |
_c21583259 _d21583259 |
||